Printer Friendly

Specialist-Oriented Products Now Account for a Growing Share of Blockbuster Drugs.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c46412) has announced the addition of the Decision Resources report "Blockbusters are Alive and Well: Why their Numbers Continue to Rise" to their offering.

Despite changes in the pharmaceutical industry and a marked slowdown in the number of new drugs launched, the blockbuster model of drug development is alive and well. Since 1986, the number of blockbuster drugs has grown continuously, and this growth shows no signs of a slowdown.

Specialist-oriented products now account for a growing share of blockbuster drugs. How will this changing product mix impact blockbuster sales? What factors must companies consider to ensure accurate forecasting for these higher-priced products? The full exploitation of blockbuster potential, both within therapeutic areas and across disease indications, has been important to industry growth. Will this trend continue even as the number of new products continues to languish? Which therapeutic areas offer the greatest potential for indication proliferation? Fears that pharmacogenomics spells the imminent demise of blockbusters are unfounded. Which recent blockbusters have proved this premise to be wrong? How can pharma companies broaden their forecasting vision for these new pharmacogenomic drugs?

Under-forecasting of blockbuster products threatens to limit the commercial potential of the industry, and higher standards of forecasting are needed. What industry factors are causing this tendency to under-forecast? How can companies combat under-forecasting in order to identify the true potential of their blockbuster products?

Scope of the report:

-- Pharmaceutical industry growth in the blockbuster era: an examination of how the industry has managed to sustain healthy growth despite the drop in new product launches.

-- Blockbusters, 2005 and 1995: an analysis of blockbusters past and present and how the mix of products has changed.

-- Why blockbuster numbers continue to rise: a discussion of indication proliferation and under-forecasting of blockbuster potential.

-- Impact of pharmacogenomics: a recent chronology of events and a discussion of the arrival and impact of pharmacogenomic blockbusters.

-- Outlook: a discussion of the dangers of under-forecasting and the need to improve forecasting going forward in order to more readily identify potential blockbusters.

Companies mentioned:

Abbott

Altana

Amgen

Astellas

AstraZeneca

Biogen Idec

Biovail

Boehringer Ingelheim

Bristol-Myers Squibb

Chugai

Daiichi Sankyo

Dainippon Sumitomo

Eisai

Forest Laboratories

Genentech

GlaxoSmithKline

Johnson & Johnson

King

Eli Lilly

Lundbeck

MedImmune

Merck

Novartis

Otsuka

Pfi zer

Procter & Gamble

Roche

Sanofi -Aventis

Schering

Schering-Plough

Serono

Takeda

Tanabe

TAP

Teva

UCB

Wyeth

For more information visit http://www.researchandmarkets.com/reports/c46412
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Dec 4, 2006
Words:404
Previous Article:39% Of Digital Printers Say Their Digital Printing Volumes Are Increasing "a Little" or "a Lot".
Next Article:Parkinson's Disease is Poised to become a Significant Public Health Burden as the Population Ages.


Related Articles
BLOCKBUSTER DEAL IN THE WORKS; VIACOM EXPECTED TO SPIN OFF LARGE BUT LACKLUSTER VIDEO RENTAL CHAIN.
AMGEN RIVALS GET OK FOR DRUG TESTING.
A WHOLE NEW BALLGAME; AFTER HOME RUNS WITH ITS FIRST TWO DRUGS, AMGEN TRIES TO PUT ITS HEPATITIS C PRODUCT IN PLAY.
Fundamental letdown: Eddie Ramos' concentration in tech-related firms betrayed his analytical approach. (Stock Update).
Drug spending soars. (Short Takes: News at Deadline).
BRIEFCASE CHEROKEE INC. HAS HIKE IN Q2 INCOME.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters